Click here to go to back to the top of the page.

Global Reporting Frameworks

Pfizer continues to evaluate our approach to non-financial reporting, including adherence to several existing, globally recognized external frameworks. These include the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB) and the International Integrated Reporting Council (IIRC). We have relied on elements of each framework in developing this year's annual review while adhering to none in its entirety. Based on feedback we received in 2015 from a few key stakeholders, we decided to include a GRI Reference Table in this Annual Review as a reference tool to help readers more readily locate relevant information across Pfizer's web-based resources.

We also take into account elements of other Environment, Social and Governance (ESG) indices and sustainability indicators, in particular the Access to Medicines Index and the UN Global Goals (also known as the Sustainable Development Goals).

GRI Indicator Description Reference
Strategy and Analysis
G4-1 CEO/Chair Statement CEO Letter — To Our Stakeholders
Organizational Profile
G4-3 Company name Pfizer Inc.
G4-4 Company brand, products and services CEO Letter — To Our Stakeholders
G4-5 Location of headquarters New York, New York (U.S.)
G4-6 Main countries of operation Global Commercial Businesses
G4-8 Markets served (e.g. sectors, customers) Global Commercial Businesses
G4-9 Scale of company (e.g. employees, sales) Performance
G4-10 Employee profile Colleagues
G4-12 Description of company supply chain Manufacturing and Supply Chain
G4-14 Precautionary approach / principle Pfizer manages and reports on our risks and impacts in consideration of the precautionary principle.
Identified Material Aspects and Boundaries
G4-17 Entities included in financial statements About This Review
G4-18 Process for defining report content About This Review
G4-19 Material issues / aspects identified About This Review
G4-23 Significant changes in scope / boundaries Pfizer footprint and capabilities grew with the Hospira acquisition, which was included in the 2015 Annual Review.
Stakeholder Engagement
G4-24 Stakeholders engaged Stakeholder Engagement
G4-25 Basis for identification of stakeholders Stakeholder Engagement
G4-26 Approach to stakeholder engagement Stakeholder Engagement
G4-27 Issues raised in stakeholder engagement Stakeholder Engagement
Report Profile
G4-28 Reporting period About This Review
G4-29 Date of previous report See Previous Annual Review
G4-30 Reporting cycle About This Review
G4-31 Reporting contact point Chris Gray, Senior Director, Corporate Responsibility
G4-32 In accordance option chosen GRI Reference Table
G4-34 Governance structure Governance and Ethics
G4-37 Governance and stakeholder engagement Stakeholder Engagement
G4-38 Composition of the Board Meet the Pfizer Board of Directors
G4-39 Chair of the Board Meet the Pfizer Board of Directors
G4-40 Nomination of Board Members The Pfizer Board: Board Policies
G4-41 Conflict of interest and the Board The Pfizer Board: Board Policies
Ethics and Integrity
G4-56 Values, principles and codes Pfizer Compliance
DMA Disclosures on Management Approach The Global Goals
G4-EC1 Direct economic value Global Reach: China
G4-EC7 Infrastructure investments and services Global Reach: India
G4-EC9 Local supplier spending Global Reach: South Africa
DMA Disclosures on Management Approach Our Green Journey
G4-EN8 Total water withdrawal by source Water Withdrawal
G4-EN23 Total waste Waste Disposed
G4-EN27 Mitigation of product impacts Pharmaceuticals in the Environment (PIE)
G4-EN32 Supplier environmental screening Manufacturing and Supply Chain
G4-EN33 Supply chain environmental impacts Pfizer Issues Supply Chain Environmental Sustainability Goal
Social: Labor Practices and Decent Work
DMA Disclosures on Management Approach Colleagues: OWNIT! Culture
G4-LA5 Health and safety committees Employee Health and Safety
G4-LA6 Injuries and work related fatalities Colleagues
G4-LA9 Employee training Driving Inclusion through Colleague Engagement
G4-LA10 Employee skills and learning Colleagues Dare to Try to Spur Growth
Social: Human Rights
DMA Disclosures on Management Approach Governance and Ethics
G4-HR2 Human rights training Colleagues: Unconscious Bias Awareness
G4-HR3 Discrimination Colleagues: Inclusion for Individuals with Disabilities and Caregivers
Social: Society
DMA Disclosures on Management Approach Governance and Ethics
G4-SO1 Local community engagement Partnering with Youth Advisory Groups
G4-SO2 Impacts on local communities Empowering Patients
G4-SO3 Anti-corruption risk Practical Ethical Sales and Marketing
G4-SO6 Political contributions Corporate and Shareholder Information
Social: Product Responsibility
DMA Disclosures on Management Approach Clinical Trials
G4-PR1 Health and safety impacts of products Manufacturing and Supply Chain
G4-PR5 Customer satisfaction Access to Medicines
G4-PR8 Customer privacy breaches Investigating with Integrity
Back to Top